BREATHNINE SYRUP 2MG5ML

Country: Малезија

Језик: Енглески

Извор: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Купи Сада

Активни састојак:

SALBUTAMOL SULPHATE

Доступно од:

SM PHARMACEUTICALS SDN. BHD.

INN (Међународно име):

SALBUTAMOL SULPHATE

Јединице у пакету:

100ml mL; 60ml mL

Произведен од:

SM PHARMACEUTICALS SDN. BHD.

Информативни летак

                                PLEASE REFER TO E12
                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                Package Insert
Page 1 of 5
SM PHARMACEUTICALS SDN. BHD.
BREATHNINE (SALBUTAMOL SULPHATE) SYRUP 2 MG / 5 ML
DESCRIPTION:
A clear, red coloured liquid with sweet taste and raspberry flavour.
COMPOSITION:
Salbutamol Sulphate equivalent to 2mg / 5ml Salbutamol.
ACTIONS AND MODE OR MECHANISMS OF ACTION:
A direct-acting sympathomimetic amine. Acts relatively selectively on
beta 2 adrenergic
receptors in the lungs to relax bronchiol smooth muscle, thereby
relieving bronchospasm
and reducing airway resistance. Also relaxes smooth muscle of the
uterus and vascular
supply to the skeletal muscle. These actions are believed to result
from increased
production of cyclic adenosine 3'5' monophosphate (cylic 3'5' -AMP)
caused by activation
of the enzyme adenyl cyclase.
PHARMACOLOGY
(SUMMARY
OF
PHARMACODYNAMICS
AND
PHARMACOKINETICS):
Absorption - Well absorbed from the gastrointestinal tract.
Metabolism - Hepatic, primarily to salbutamol 4'-0 sulfate which has
little or no beta-
adrenergic blocking activity..
Half life - (plasma) 2.7 to 5 hours.
Onset of action - within 30 minutes
Time to peak plasma concentration - within 2 to 3 hours following a 6
mg of tritiated
salbutamol sulphate.
Time to peak effect – 2 to 3 hours.
Duration of action – 6 hours or longer.
Excretion - Renal; approximately 76% of oral dose excreted over 3 days
in the urine, the
majority of dose being excreted within the first 24 hours, consisting
of 60% as metabolites.
Faecal; About 4% of oral dose may be excreted in the faeces.
INDICATIONS:
a. Relief of broncial asthma
b. Chronic bronchitis
c. Emphysema
d. Acute dyspnea
CONTRAINDICATIONS:
Use of this medication should be carefully considered when the
following medical
problems exist (reasons given where appropriate).
Cardiovascular disorders, including coronary insufficiency and
hypertension.
Package Insert
Page 2 of 5
Diabetes mellitus, Enlarged prostate, Hyperthyroidism.
SIDE EFFECTS / ADVERSE REACTIONS:
Fine
tremor
(usually
hands),
nervous
tension,
headache,
peripheral
vasodilation,
tachycardia (seldom
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Малајски 06-06-2017

Обавештења о претрази у вези са овим производом

Погледајте историју докумената